Bristol-Myers Squibb Company (SIX: BMY.SW) Stock Competitors & Peer Comparison

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, LLY.SW has a market cap of 851.6B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while LLY.SW trades at CHF 955.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas LLY.SW's P/E ratio is 37.94. In terms of profitability, BMY.SW's ROE is +0.45%, compared to LLY.SW's ROE of +0.93%. Regarding short-term risk, BMY.SW is similarly volatile compared to LLY.SW. This indicates similar risk in terms of short-term price fluctuations for BMY.SW.Check LLY.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, JNJ.SW has a market cap of 535.1B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while JNJ.SW trades at CHF 222.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas JNJ.SW's P/E ratio is 25.26. In terms of profitability, BMY.SW's ROE is +0.45%, compared to JNJ.SW's ROE of +0.26%. Regarding short-term risk, BMY.SW is similarly volatile compared to JNJ.SW. This indicates similar risk in terms of short-term price fluctuations for BMY.SW.Check JNJ.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, RO.SW has a market cap of 286B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while RO.SW trades at CHF 364.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas RO.SW's P/E ratio is 21.87. In terms of profitability, BMY.SW's ROE is +0.45%, compared to RO.SW's ROE of +0.37%. Regarding short-term risk, BMY.SW is less volatile compared to RO.SW. This indicates lower risk in terms of short-term price fluctuations for BMY.SW.Check RO.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, ROP.SW has a market cap of 284B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while ROP.SW trades at CHF 356.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas ROP.SW's P/E ratio is 18.34. In terms of profitability, BMY.SW's ROE is +0.45%, compared to ROP.SW's ROE of +0.37%. Regarding short-term risk, BMY.SW is less volatile compared to ROP.SW. This indicates lower risk in terms of short-term price fluctuations for BMY.SW.Check ROP.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, ROG.SW has a market cap of 256.6B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while ROG.SW trades at CHF 322.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas ROG.SW's P/E ratio is 20.11. In terms of profitability, BMY.SW's ROE is +0.45%, compared to ROG.SW's ROE of +0.41%. Regarding short-term risk, BMY.SW is less volatile compared to ROG.SW. This indicates lower risk in terms of short-term price fluctuations for BMY.SW.Check ROG.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, NOVN.SW has a market cap of 218.8B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while NOVN.SW trades at CHF 115.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas NOVN.SW's P/E ratio is 16.75. In terms of profitability, BMY.SW's ROE is +0.45%, compared to NOVN.SW's ROE of +0.30%. Regarding short-term risk, BMY.SW is less volatile compared to NOVN.SW. This indicates lower risk in terms of short-term price fluctuations for BMY.SW.Check NOVN.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, GILD.SW has a market cap of 143.2B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while GILD.SW trades at CHF 115.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas GILD.SW's P/E ratio is -290.93. In terms of profitability, BMY.SW's ROE is +0.45%, compared to GILD.SW's ROE of -0.17%. Regarding short-term risk, BMY.SW is similarly volatile compared to GILD.SW. This indicates similar risk in terms of short-term price fluctuations for BMY.SW.Check GILD.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, GSK.SW has a market cap of 101.6B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while GSK.SW trades at CHF 19.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas GSK.SW's P/E ratio is 18.76. In terms of profitability, BMY.SW's ROE is +0.45%, compared to GSK.SW's ROE of +0.38%. Regarding short-term risk, BMY.SW is not fully comparable compared to GSK.SW. This indicates unavailable risk data in terms of short-term price fluctuations for BMY.SW.Check GSK.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, BAYN.SW has a market cap of 45.5B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while BAYN.SW trades at CHF 46.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas BAYN.SW's P/E ratio is 10.33. In terms of profitability, BMY.SW's ROE is +0.45%, compared to BAYN.SW's ROE of -0.06%. Regarding short-term risk, BMY.SW is similarly volatile compared to BAYN.SW. This indicates similar risk in terms of short-term price fluctuations for BMY.SW.Check BAYN.SW's competition here

Bristol-Myers Squibb Company (SIX: BMY.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY.SW stands at 87.7B. In comparison, BIIB.SW has a market cap of 20.8B. Regarding current trading prices, BMY.SW is priced at CHF 52.75 on the SIX, while BIIB.SW trades at CHF 141.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY.SW currently has a P/E ratio of 10.13, whereas BIIB.SW's P/E ratio is 11.19. In terms of profitability, BMY.SW's ROE is +0.45%, compared to BIIB.SW's ROE of +0.05%. Regarding short-term risk, BMY.SW is similarly volatile compared to BIIB.SW. This indicates similar risk in terms of short-term price fluctuations for BMY.SW.Check BIIB.SW's competition here